Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement

Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor

(2009) Camilo Rojas et al.   ANESTHESIA AND ANALGESIA

Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

(2009) M Musso et al.   BONE MARROW TRANSPLANTATION

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

(2009) Karin Jordan et al.   EUROPEAN JOURNAL OF CANCER

Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support

(2009) Betsy Paul et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Chemotherapy and cancer related nausea and vomiting

(2008) David Warr   Current Oncology

American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges

(2008) Mark R. Somerfield et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study

(2008) Alessandra Fabi et al.   SUPPORTIVE CARE IN CANCER

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

(2008) Paul J. Hesketh et al.   SUPPORTIVE CARE IN CANCER